Non-invasive Biomarker Discovery for Pre-cervical or/and Cervical Cancer-HPV DNA and Other Biomarkers in Urine
The goal of this clinical trial is
To test the sensitivity and specificity of using HPV DNA from urine for the detection of pre-cervical or/and cervical cancer.
If HPV DNA is not a promising biomarker, other biomarkers will be explored.
To develop an effective and non-invasive detection method of the pre-cervical or/and cervical cancer. in Women with menstruation.
The main question it aims to answer is:
To validate whether HPV DNA from urine could be used as a non-invasive means for the detection of pre-cervical or cervical cancer
Participants will
Join the briefing session of the study
Sign the consent form and health questionnaire
Submit the cervical medical report(s) within 3 months or perform sponsored pap smear test
Collect the urine sample
If there is a comparison group: Researchers will compare The diseased group and the healthy group according to the medical reports they provided to see if HPV DNA from urine is a promising biomarker for the detection of pre-cervical or cervical cancer
Non-invasive Biomarker Discovery for Pre-cervical or/and Cervical Cancer--ACTN4 and Other Biomarkers in Menstrual Blood
The goal of this clinical trial is
To test the sensitivity and specificity of using ACTN4 from menstrual blood for the detection of pre-cervical or/and cervical cancer.
If ACTN4 is not a promising biomarker, other biomarkers will be explored.
To develop an effective and non-invasive detection method for pre-cervical or/and cervical cancer.
in Women with menstruation.
The main question it aims to answer is:
To validate whether menstrual blood could be used as a non-invasive means for the detection of pre-cervical or cervical cancer
Participants will
Join the briefing session of the study
Sign the consent form and health questionnaire
Submit the cervical medical report(s) within 3 months or perform sponsored pap smear test
Collect the menstrual blood sample
If there is a comparison group: Researchers will compare The diseased group and the healthy group according to the medical reports they provided to see if ACTN4 from menstrual blood is a promising biomarker for the detection of pre-cervical or cervical cancer
100 项与 樺盟生物科技有限公司 相关的临床结果
0 项与 樺盟生物科技有限公司 相关的专利(医药)
100 项与 樺盟生物科技有限公司 相关的药物交易
100 项与 樺盟生物科技有限公司 相关的转化医学